[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ascletis Pharma (China) Co., Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100650045","phase-3-a-study-of-once-daily-oral-asc30-to-evaluate-the-efficacy-and-safety-in-adult-participants-with-obesity-or-overweight-with-type-2-diabetes-100650045",false,"NCT07743450","A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes","A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Type 2 Diabetes Mellitus (AURORA-2)","AURORA-2","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening.\n2. Have a BMI ≥ 27 kg\u002Fm2 at screening.\n3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n4. Have a diagnosis of T2D according to the WHO classification or other locally applicable standards, with HbA1c \\> 6.5% (48 mmol\u002Fmol) to ≤10.5% (91 mmol\u002Fmol) at screening.\n\nExclusion Criteria:\n\n1. Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar state\u002Fcoma, or any other types of diabetes except T2DM.\n2. Have a self-reported change in body weight \\>5 kg (11 pounds) within 3 months prior to screening.\n3. Have an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73 m2, as determined by the laboratory at screening.\n4. Have a history of acute or chronic pancreatitis any time prior to screening.\n5. Have known allergies or intolerance to glucagon-like peptide-1 Receptor Agonists (GLP-1 RA).\n6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\n7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.","ALL","18 Years",{"count":20,"type":21},1560,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.",[27,28,29,30],"Obesity","Overweight","Chronic Weight Management","Type 2 Diabetes Mellitus",[27,28,32],"Type 2 Diabetes","RECRUITING","2026-08-12",{"date":36,"type":37},"2026-08-14","ACTUAL",{"date":39,"type":21},"2026-08",{"date":41,"type":21},"2028-07",{"name":43,"class":44},"Ascletis Pharma (China) Co., Limited","INDUSTRY",136,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":64,"locationsCount":65},"100649973","phase-3-a-study-of-once-daily-oral-asc30-to-evaluate-the-efficacy-and-safety-in-adult-participants-with-obesity-or-overweight-with-weight-related-comorbidities-100649973","NCT07743463","A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities","A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)","AURORA-1","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening.\n2. Have a BMI ≥ 30 kg\u002Fm2 or a BMI ≥ 27 kg\u002Fm2 and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening:\n\n   * Hypertension\n   * Dyslipidemia\n   * Obstructive sleep apnea\n   * Cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure).\n3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state\u002Fcoma. Participants with a history of gestational diabetes are eligible to participate in this trial.\n2. Have a self-reported change in body weight \\>5 kg (11 pounds) within 3 months prior to screening.\n3. Have an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73 m2, as determined by the laboratory at screening.\n4. Have a history of acute or chronic pancreatitis any time prior to screening.\n5. Have known allergies or intolerance to other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs.\n6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\n7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.",{"count":55,"type":21},3003,[24],"Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.",[27,28,29],[27,28,60],"Weight Management",{"date":36,"type":37},{"date":39,"type":21},{"date":41,"type":21},{"name":43,"class":44},120,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100594834","phase-1-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-pharmacodynamics-and-efficacy-of-asc50-tables-in-healthy-participants-and-participants-with-plaque-psoriasis-100594834","NCT07024602","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis","A Phase I, Randomized, Double-blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of ASC50 Tablets in Healthy Adult Participants and Adult Participants With Mild to Moderate Plaque Psoriasis","Inclusion Criteria:\n\n1. Male and female participants between 18 to 65 years of age inclusive, at the time of screening.\n2. Willing and able to give informed consent prior to any study specific procedures being performed.\n3. Have venous access sufficient to allow for blood sampling\n\nExclusion Criteria:\n\n1. Female participants who are pregnant, breastfeeding or plan to be pregnant during the study period and 3 months after last dose.\n2. History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the subject's safety during the clinical study or expose the subject to undue risk as judged by the Investigator.\n3. Have received systemic immunosuppressive therapy (MTX, apremilast, azathioprine, cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, and tacrolimus) within 4 weeks of first administration of study drug.\n4. Have any other conditions, which, in the opinion of the investigator or sponsor, would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study.",true,"65 Years",{"count":76,"type":21},94,[78],"PHASE1","This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult participants and adult participants with mild to moderate plaque psoriasis.",[81],"Plaque Psoriasis",[83,81],"ASC50","2025-06-09",{"date":86,"type":37},"2025-06-17",{"date":88,"type":21},"2025-06",{"date":90,"type":21},"2026-06",{"name":43,"class":44},1,""]